Altshuler Shaham LTD Eloxx Pharmaceuticals, Inc. Transaction History

Altshuler Shaham LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.15 - $7.2 $10,904 - $523,425	-72,698 Reduced 6.75%	1,004,963 $153,000
Q2 2022 Aug 10, 2022	SELL	$0.24 - $0.58 $2,684 - $6,488	-11,187 Reduced 1.03%	1,077,661 $291,000
Q1 2022 May 16, 2022	SELL	$0.4 - $0.72 $27,476 - $49,458	-68,692 Reduced 5.93%	1,088,848 $609,000
Q2 2020 Aug 13, 2020	BUY	$1.56 - $3.65 $25,612 - $59,925	16,418 Added 1.44%	1,157,540 $3.51 Million
Q1 2020 May 12, 2020	BUY	$1.96 - $7.96 $90,363 - $366,987	46,104 Added 4.21%	1,141,122 $2.24 Million
Q3 2019 Nov 12, 2019	BUY	$4.37 - $9.91 $5,064 - $11,485	1,159 Added 0.11%	1,095,018 $4.9 Million
Q2 2019 Aug 06, 2019	BUY	$8.77 - $12.49 $2.13 Million - $3.03 Million	242,962 Added 28.55%	1,093,859 $11.3 Million
Q1 2019 May 15, 2019	BUY	$10.45 - $13.94 $96,495 - $128,721	9,234 Added 1.1%	850,897 $9.94 Million
Q4 2018 Feb 11, 2019	SELL	$10.43 - $17.39 $3,765 - $6,277	-361 Reduced 0.04%	841,663 $10.1 Million
Q3 2018 Nov 13, 2018	BUY	$11.95 - $19.63 $10.1 Million - $16.5 Million	842,024 New	842,024 $14.3 Million

Ticker ELOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,656,200
Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis p...

Get notified when there are updates to the investment portfolio of Altshuler Shaham LTD, based on Form 13F filings with the SEC.

Stay updated on Altshuler Shaham LTD with notifications on news.